Topics

Bayer, Arvinas Partner on PROTAC Joint Venture, Treatments for Cancer, CV, Gynecological Diseases

08:00 EDT 2 Oct 2019 | Genetic Engineering News

Bayer and Arvinas said they have finalized terms for a joint venture that will apply Arvinas’ platform for engineering proteolysis-targeting chimeras (PROTAC®) protein degraders in order to develop sustainable products that control diseases, pests, and weeds by addressing resistance mechanisms in plants.

The post Bayer, Arvinas Partner on PROTAC Joint Venture, Treatments for Cancer, CV, Gynecological Diseases appeared first on GEN - Genetic Engineering and Biotechnology News.

Original Article: Bayer, Arvinas Partner on PROTAC Joint Venture, Treatments for Cancer, CV, Gynecological Diseases

NEXT ARTICLE

More From BioPortfolio on "Bayer, Arvinas Partner on PROTAC Joint Venture, Treatments for Cancer, CV, Gynecological Diseases"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...